Christopher Bowden's most recent trade in Bicara Therapeutics Inc. was a trade of 19,475 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | Dr. Christopher Bowden, M.D. | Director | 09 Jun 2026 | 19,475 | 19,475 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. Christopher Bowden, M.D. | Director | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | ||
| Alaunos Therapeutics Inc | Dr. Christopher Bowden, M.D. | Director | 22 Jun 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | ||
| Alaunos Therapeutics Inc | Dr. Christopher Bowden, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 40,000 | 44,167 (0%) | 0% | 0 | Common Stock |